Structure of Tepotinib
CAS No.: 1100598-32-0
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, > 200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.
Synonyms: EMD 1214063; MSC2156119; EMD-1214063
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1100598-32-0 |
Formula : | C29H28N6O2 |
M.W : | 492.57 |
SMILES Code : | N#CC1=CC=CC(C(C=C2)=NN(CC3=CC=CC(C4=NC=C(OCC5CCN(C)CC5)C=N4)=C3)C2=O)=C1 |
Synonyms : |
EMD 1214063; MSC2156119; EMD-1214063
|
MDL No. : | MFCD18452823 |
InChI Key : | AHYMHWXQRWRBKT-UHFFFAOYSA-N |
Pubchem ID : | 25171648 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302 |
Precautionary Statements: | P280-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
EBC-1 | 5 µM | 12 months | To generate Tepotinib-resistant cell lines to study resistance mechanisms. | PMC7718487 |
Hs746T | 5 µM | 12 months | To generate Tepotinib-resistant cell lines to study resistance mechanisms. | PMC7718487 |
SNU620 | 9 nM | 48 hours | Tepotinib significantly induced apoptosis in SNU620 cells and significantly reduced the protein levels of phosphorylated and total c-MET, phosphorylated and total ERK, β-catenin, and c-MYC. | PMC7503648 |
MKN45 | 7 nM | 48 hours | Tepotinib significantly induced apoptosis in MKN45 cells and significantly reduced the protein levels of phosphorylated and total c-MET, phosphorylated and total ERK, β-catenin, and c-MYC. | PMC7503648 |
KATO III | 10 nM | 48 hours | Tepotinib significantly induced apoptosis in KATO III cells but had minimal effects on the protein levels of phosphorylated and total c-MET, phosphorylated and total ERK, β-catenin, and c-MYC. | PMC7503648 |
MHCC97H cells | 10 nM | 48 hours | To evaluate the antiproliferative activity of compound 8b, the results showed an IC50 value of 10 nM against MHCC97H cells. | PMC9921947 |
H358 | 0-18 µM | 72 hours | To evaluate the antitumor effects of Tepotinib in combination with Omeprazole, the results showed that the combination significantly reduced cell viability. | PMC11167791 |
A549 | 0-7.9 µM | 72 hours | To evaluate the antitumor effects of Tepotinib in combination with Omeprazole, the results showed that the combination significantly reduced cell viability. | PMC11167791 |
NCI-H460/TPT10 cells | 1 and 3 μM | Tepotinib significantly enhanced the cytotoxicity of ABCG2 substrate drugs mitoxantrone and topotecan, reducing the IC50 values in drug-resistant cells. | PMC9136566 | |
HEK293/ABCG2-WT cells | 1 and 3 μM | Tepotinib significantly enhanced the cytotoxicity of ABCG2 substrate drugs mitoxantrone and topotecan, reducing the IC50 values in drug-resistant cells. | PMC9136566 | |
HCCLM3 cells | 0.013 µM | To evaluate the cytotoxicity of compound 8b against HCCLM3 cells, the results showed an IC50 value of 0.013 μM. | PMC9921947 | |
LO2 cells | 4.314 µM | To evaluate the cytotoxicity of compound 8b against LO2 cells, the results showed an IC50 value of 4.314 μM. | PMC9921947 | |
97H cells (human liver cancer cells) | 0.013 µM (IC50) | To evaluate the anti-tumor activity of the compounds, compound 31e showed the best inhibitory effect with an IC50 value of 26 nM | PMC6470795 | |
Pc9 cells (human non-small cell lung cancer cells) | 8.105 μM (IC50) | To evaluate the inhibitory activity of compound 31e against Pc9 cells, the IC50 value was 42.9 μM | PMC6470795 | |
Hela cells (human epithelial cervical cancer cells) | 11.22 μM (IC50) | To evaluate the inhibitory activity of compound 31e against Hela cells, the IC50 value was >50 μM | PMC6470795 | |
SJSA1 cells (human osteosarcoma cells) | 12.17 μM (IC50) | To evaluate the inhibitory activity of compound 31e against SJSA1 cells, the IC50 value was >50 μM | PMC6470795 | |
LO2 cells (human normal liver cells) | 10.33 μM (IC50) | To evaluate the inhibitory activity of compound 31e against LO2 cells, the IC50 value was >50 μM | PMC6470795 | |
HLF cells (human embryonic lung fibroblast cells) | 9.44 μM (IC50) | To evaluate the inhibitory activity of compound 31e against HLF cells, the IC50 value was >50 μM | PMC6470795 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Nude mice | NCI-H460/TPT10 tumor xenograft model | Subcutaneous injection | 30 mg/kg | Every 3 days until the end of the experiment | Tepotinib significantly enhanced the antitumor effect of topotecan in drug-resistant tumors, increasing intratumoral drug accumulation. | PMC9136566 |
Nu/Nu mice | H358 cell-derived tumor xenograft model | Subcutaneous injection | 5 mg/kg | Once daily for three weeks | To evaluate the in vivo antitumor effects of Tepotinib in combination with Omeprazole, the results showed that the combination significantly inhibited tumor growth. | PMC11167791 |
Rat | Sprague‒Dawley rats | Oral | 50 mg/kg | Single dose | To study the drug-drug interaction between Tepotinib and naringenin, the results showed that naringenin significantly increased the plasma exposure of Tepotinib and decreased its clearance rate. | PMC11536652 |
Nude mice | MKN45 xenograft model | Oral | 10 mg/kg | Once daily for 3 weeks | Tepotinib significantly inhibited tumor growth and increased ECAD expression while decreasing phosphorylated c-MET protein levels. | PMC7503648 |
Mice | EBC-1 xenograft model | Oral | 5 mg/kg | Once daily, continuous treatment | To evaluate the inhibitory effect of Tepotinib in combination with SHP2 inhibitor on tumor growth. | PMC7718487 |
Mice | NSCLC xenograft models | Oral gavage | 100 mg/kg | Daily for 32 days | To evaluate the antitumor effects of Tepotinib in combination with various EGFR TKIs in NSCLC xenograft models. The results showed that Tepotinib combined with EGFR TKIs effectively inhibited tumor growth, especially in models with high c-Met expression, where Tepotinib alone or in combination exhibited significant antitumor activity. | PMC5411803 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT04647838 | Solid Tumor|MET Exon 14 Skippi... More >>ng Mutation|MET Amplification Less << | PHASE2 | UNKNOWN | 2024-08-31 | Chonnam National University Hw... More >>asun Hospital, Hwasun, Chonnam, Korea, Republic of|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, 28644, Korea, Republic of|Dankook University Hospital, Cheonan, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|Konyang University Hospital, Daejeon, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|The Catholic University of Korea Incheon St. Marry Hospital, Incheon, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|Inje University Haeundae Pain Hospital, Pusan, Korea, Republic of|Kosin University Gaspel Hospital, Pusan, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Chungang University Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of Less << |
NCT02864992 | Advanced (Stage IIIB/IV) Non-s... More >>mall Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification|Lung Adenocarcinoma Stage IIIB/IV Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-10-31 | City of Hope Cancer Center, Du... More >>arte, California, 91010, United States|California Cancer Associates for Research & Excellence, Inc., Encinitas, California, 92024, United States|St. Joseph Hospital, Orange, California, 92868-4225, United States|Torrance Health Association, Redondo Beach, California, 90277, United States|St Joseph Heritage Healthcare, Santa Rosa, California, 95403, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, 80218, United States|Holy Cross Hospital Inc., Fort Lauderdale, Florida, 33308, United States|H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, 33612-9497, United States|University Cancer & Blood Center, LLC, Athens, Georgia, 30607, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Ingalls Hospital, Harvey, Illinois, 60426-3558, United States|Community Regional Cancer Care, Indianapolis, Indiana, 46250, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, 20817, United States|For Recruiting Locations in the United States, please Contact U.S. Medical Information, Rockland, Massachusetts, United States|St. Louis Cancer Care, LLP, Bridgeton, Missouri, 63044, United States|Saint Louis University Cancer Center, Saint Louis, Missouri, 63110, United States|Saint Louis University, Saint Louis, Missouri, 63110, United States|Summit Medical Group, P.A., Berkeley Heights, New Jersey, 07922, United States|Summit Medical Group, Berkeley Heights, New Jersey, 07922, United States|Regional Cancer Care Associates East Brunswick, East Brunswick, New Jersey, 08816, United States|Somerset Hematology Oncology Associates - Somerville Location, East Brunswick, New Jersey, 8816, United States|Hackensack University Medical Center PARTNER, Hackensack, New Jersey, 07601, United States|Prospect Medical Offices, LLC, Midland Park, New Jersey, 07432, United States|The Valley Hospital, Ridgewood, New Jersey, 07450, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Cancer Center, West Harrison Regional Outpatient Pavilion, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10022, United States|UC Health Clinical Trials Office, Cincinnati, Ohio, 45229, United States|University of Cincinnati - PARENT, Cincinnati, Ohio, 45267-0502, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Texas Oncology, P.A. - Austin, Austin, Texas, 78731, United States|Texas Oncology, PA, Beaumont, Texas, 77702-1449, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|Swedish Medical Center, Seattle, Washington, 98104, United States|Wenatchee Valley Hospital & Clinics - ATTN: Jay Johnson, Wenatchee, Washington, 98801, United States|Wenatchee Valley Medical Center Oncology, Wenatchee, Washington, 98801, United States|LKH - Universit?tsklinikum der PMU Salzburg - Innere Med III/H?matologie und Onkologie, Salzburg, Austria|UZ Antwerpen, Edegem, 2650, Belgium|UZ Antwerpen, Edegem, Belgium|CHU Ambroise Paré, Mons, 7000, Belgium|CHU Ambroise Paré, Mons, Belgium|AZ Delta, Roeselare, 8800, Belgium|AZ Delta, Roeselare, Belgium|Beijing Hospital, Beijing, China|Peking University Cancer Hospital, Beijing, China|Jilin Cancer Hospital - Oncology, Changchun, China|Hunan Cancer Hospital, Changsha, China|Sichuan Cancer Hospital, Chengdu, China|West China Hospital, Sichuan University, Chengdu, China|Guangdong General Hospital, Guangzhou, China|Zhejiang Cancer Hospita, Hangzhou, China|Affiliated Tumor Hospital of Harbin Medical University, Harbin, China|Anhui Provincial Cancer Hospital aka West Branch of Anhui Province Hospital, Hefei City, China|Jinan Central Hospital, Jinan, China|Linyi Tumor Hospital, Linyi, China|Jiangsu Province Hospital, Nanjing, China|Shanghai Cancer Hospital, Fudan University, Shanghai, China|Liaoning Cancer Hospital & Institute, Shenyang, China|The Affiliated Cancer Hospital of Xinjiang Medical university, Urumqi, China|Groupe Hospitalier Sud - H?pital Haut-Lévêque, Pessac, Gironde, 33604, France|CHU de Toulouse - H?pital Larrey, Toulouse, Haute Garonne, 31059, France|ICO - Site René Gauducheau, Saint Herblain, Loire Atlantique, 44805, France|Clinique Mutualiste de l'Estuaire, Saint Nazaire Cedex, Loire Atlantique, 44606, France|ICO - Site Paul Papin, Angers Cedex 2, Maine Et Loire, 49055, France|Centre Hospitalier de Cholet, Cholet, Maine Et Loire, 49300, France|Centre Hospitalier de Bretagne Sud, Lorient cedex, Morbihan, 56322, France|Hopital Albert Calmette - CHU Lille, Lille Cedex, Nord, 59037, France|Centre Hospitalier de la c?te Basque, Bayonne, Pyrenees Atlantiques, 64100, France|Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, Vendee, 85925, France|ICO - Site Paul Papin, Angers Cedex 2, France|Centre Hospitalier de la c?te Basque, Bayonne, France|Centre Hospitalier de Cholet, Cholet, France|Centre Hospitalier Intercommunal de Créteil, Creteil cedex, France|Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, France|Hopital Albert Calmette - CHU Lille, Lille Cedex, France|Centre Hospitalier de Bretagne Sud, Lorient cedex, France|H?pital Saint-Louis, Paris Cedex 10, France|Groupe Hospitalier Sud - H?pital Haut-Lévêque, Pessac, France|ICO - Site René Gauducheau, Saint Herblain, France|Clinique Mutualiste de l'Estuaire, Saint Nazaire Cedex, France|CHU de Toulouse - H?pital Larrey, Toulouse, France|POIS Leipzig GbR, Leipzig, Sachsen, 04357, Germany|Charite Universitaetsmedizin Berlin - Campus Charite Mitte, Berlin, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|For Recruiting Locations outside US, please Contact Merck KGaA Communication Center, Darmstadt, Germany|Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt, Dresden, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Asklepios Fachkliniken Muenchen-Gauting, Gauting, Germany|SRH Wald-Klinikum Gera gGmbH, Gera, Germany|Universitaetsmedizin Goettingen, Goettingen, Germany|Evangelisches Krankenhaus Hamm GmbH, Hamm, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Universitaetsklinikum des Saarlandes, Homburg / Saar, Germany|POIS Leipzig GbR, Leipzig, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|Soroka University Medical Center, Beer-Sheva, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Meir Medical Center, Kfar- Saba, Israel|Rabin Medical Center-Beilinson Campus, Petach Tikva, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Istituto Nazionale per la Ricerca sul Cancro di Genova, Genova, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, 20133, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IEO Istituto Europeo di Oncologia, Milano, Italy|Seconda Università degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy|Ospedale Santa Maria di Cà Foncello, Padova, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Università Campus Bio-Medico di Roma, Roma, Italy|Istituto Clinico Humanitas, Rozzano, Italy|NHO Kyushu Medical Center, Fukuoka-shi, Japan|National Cancer Center Hospital East, Kashiwa-shi, Japan|Saitama Cancer Center, Kitaadachi-gun, Japan|Kurume University Hospital, Kurume-shi, Japan|NHO Shikoku Cancer Center, Matsuyama-shi, Japan|Nagoya University Hospital, Nagoya-shi, Japan|Niigata Cancer Center Hospital, Niigata-shi, Japan|Osaka International Cancer Institute, Osaka-shi, Japan|NHO Kinki-Chuo Chest Medical Center, Sakai-shi, Japan|Hokkaido University Hospital, Sapporo-shi, Japan|NHO Yamaguchi - Ube Medical Center, Ube-shi, Japan|Kanagawa Cancer Center, Yokohama-shi, Japan|Tottori University Hospital, Yonago-shi, Japan|Dong-A University Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Kyungpook National University Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Korea, Republic of|Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|VU Medisch Centrum, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen (UMCG) - Parent, Groningen, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku - Dept of Pulmonology & Tuberculosis, Bialystok, Poland|Centrum Pulmonologii i Torakochirurgii w Bystrej, Bystra, Poland|Dr n med. Slawomir Mandziuk Specjalistyczna Praktyka Lekarska, Lublin, Poland|NZOZ Olsztynski Osr. Onkologiczny "Kopernik" Sp.z o.o, Olsztyn, Poland|Przychodnia Med-Polonia Sp. z o.o., Poznan, 60-693, Poland|Przychodnia Med-Polonia Sp. z o.o., Poznan, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, 02-781, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Universitari Quiron Dexeus, Barcelona, Spain|Hospital Universitari Sagrat Cor, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital General Universitario Santa Lucia, Cartagena, Spain|Hospital de Especialidades de Jerez de la Frontera - Servicio de Oncologia, Jerez de la Frontera, Spain|Hospital Universitario HM Madrid Sanchinarro, Madrid, 28050, Spain|Hospital General Universitario Gregorio Mara?on, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario HM Madrid Sanchinarro, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario Infanta Sofia, San Sebastian de los Reyes, Spain|Hospital General de Catalunya, Sant Cugat del Valles, Spain|Hospital Universitario Virgen Macarena, Sevilla, 41009, Spain|Hospital Universitario Nuestra Se?ora de Valme, Sevilla, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Inselspital - Universitaetsspital Bern - Klinik und Poliklinik für Medizinische Onkologie, Bern, Switzerland|Universitaetsspital Zuerich - Klinik fuer Onkologie, Zuerich, Switzerland|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan Less << |
NCT04739358 | Advanced Non-Small Cell Lung C... More >>ancer With MET Mutations Less << | PHASE1|PHASE2 | TERMINATED | 2023-06-23 | UC Davis Comprehensive Cancer ... More >>Center, Sacramento, California, 95817, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, 20007, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|University of Washington, Seattle, Washington, 98195, United States Less << |
NCT03546608 | Hepatic Impairment | PHASE1 | COMPLETED | 2019-02-05 | Qps Mra, Llc, Miami, Florida, ... More >>33143, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less << |
Tags: Tepotinib | MSC2156119 | EMD-1214063 | EMD 1214063 | c-Met inhibitor | MET inhibitor | c-Met phosphorylation | NSCLC | hepatocellular carcinoma | IRAK4 | TrkA | Axl | IRAK1 | Mer | tyrosine kinase inhibitor | TKI | 1100598-32-0
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL